Barclays sees Hims sales growth amid near-term profit pressure

Hims & Hers Health

20/08/2026 14:43

** Shares of telehealth company Hims & Hers Health HIMS.N rise 4% to $32.35 in early trading
** Barclays says expects higher revenues at HIMS, driven by acquisitions and impressive growth in new categories
** Sees, however, "some margin pressure from investments to support growth" that could weigh on near-time profitability
** The brokerage cuts PT on the stock to $35 from $39; maintains "overweight" rating 
** New PT represents a 12% upside to the stock's last close
** Earlier this month, HIMS topped Q2 revenue expectations while facing increasing costs from aggressive push into branded GLP-1 weight-loss drugs and international expansion
** Four of 16 brokerages rate the stock "buy" or higher and 12 "hold"; their median PT is $30.5 - data compiled by LSEG 
** Up to last close, stock down 4.3% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))